Article Text

Download PDFPDF

620 Multimodal real world data reveals immunogenomic drivers of acquired and primary resistance to immune checkpoint blockade
  1. Mohamed Reda Keddar1,
  2. Sebastian Carrasco Pro2,
  3. Kathleen Burke2,
  4. Roy Rabbie1,
  5. Ana Stewart1,
  6. Mark Cobbold3,
  7. Ross Stewart4,
  8. Benjamin Sidders1,
  9. Sajan Khosla1,
  10. Scott Hammond3,
  11. Douglas C Palmer3,
  12. Jonathan R Dry2 and
  13. Martin L Miller1
  1. 1AstraZeneca, Cambridge, Cambridgeshire, UK
  2. 2Tempus Labs Inc, Boston, MA, USA
  3. 3AstraZeneca, Gaithersburg, MD, USA
  4. 4AstraZeneca, Cambridge, UK
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Why some patients fail or have short lived response to immune checkpoint blockade (ICB) immunotherapy remains largely unknown. While baseline molecular assessments have provided clues to prognostic factors, insights into resistance drivers remains elusive. This is partially due to the difficulty in getting access to post progression samples from patients that were either primary resistant or developed acquired resistance after an initial response to ICB. Thus, the tumour-intrinsic and -extrinsic features that are selected for during progression and potentially drive primary and acquired resistance to immunotherapy remain underexplored.

Methods To compare clinical features and immunogenomic drivers of acquired and primary resistance to ICB across major cancers, we analysed and annotated de-identified patient records in the Tempus real-world database1 2 (figure 1). We built an immuno-oncology cohort consisting of >2500 multimodal (DNA, RNA and clinical outcome data) pre-treatment baseline with >1500 post-treatment tumour biopsy samples from mainly NSCLC, TNBC, HNC and Bladder cancer patients. We used bulk RNA-seq data to estimate activation of the hallmark oncogenic pathways3 and immune cell composition4 and used panel DNA-seq data (>500 genes) to quantify mutation selection at the gene and pathway levels using dndscv.5

Results Compared to acquired, primary resistant patients tended to have a higher observation of liver lesions at progression. Post-ICB, acquired resistant NSCLC and HNC patients showed a significantly inflamed tumour microenvironment (TME) characterised by higher estimation of infiltration of T cells and myeloid cells and higher activation of interferon gamma (IFNg) signalling as compared to primary resistant patients. In addition, in post-ICB acquired resistance in NSCLC we observed selection for mutations in genes involved in known immunomodulatory pathways, including loss-of-function mutations in B2M in the antigen processing and presentation machinery (APM) pathway and APC in the Wnt pathway. Consistently, acquired resistance patients showed stronger selection for mutations in APM, IFN, WNT, MYC, and Notch pathways as compared to primary resistance patients across NSCLC, HNC and bladder cancer post-ICB.

Conclusions Acquired and primary ICB resistant patients have distinct clinical and molecular features at progression. Their tumours’ TME is fundamentally different with acquired resistance TMEs being infiltrated with immune cells albeit escaped post progression. In addition, ICB selects mutations that potentially activate immunosuppressive pathways such as Wnt and Myc. This multi-modal Real-World Data with post therapy biopsies has given insights for patient selection strategies and provides rational into combination treatment options for acquired resistant patients.

References 1. Fernandes LE, Epstein CG, Bobe AM, Bell JSK, Stumpe MC, Salazar ME, Salahudeen AA, Pe Benito RA, McCarter C, Leibowitz BD, Kase M, Igartua C, Huether R, Hafez A, Beaubier N, Axelson MD, Pegram MD, Sammons SL, O’Shaughnessy JA, Palmer GA. Real-world evidence of diagnostic testing and treatment patterns in US patients with breast cancer with implications for treatment biomarkers from RNA sequencing data. Clin Breast Cancer. 2021 Aug;21(4):e340-e361. doi: 10.1016/j.clbc.2020.11.012. Epub 2020 Dec 18. PMID: 33446413.

2. Rivera DR, Henk HJ, Garrett-Mayer E, Christian JB, Belli AJ, Bruinooge SS, Espirito JL, Sweetnam C, Izano MA, Natanzon Y, Robert NJ, Walker MS, Cohen AB, Boyd M, Enewold L, Hansen E, Honnold R, Kushi L, Mishra Kalyani PS, Pe Benito R, Sakoda LC, Sharon E, Tymejczyk O, Valice E, Wagner J, Lasiter L, Allen JD. The friends of cancer research real-world data collaboration pilot 2.0: methodological recommendations from oncology case studies. Clin Pharmacol Ther. 2022 Jan;111(1):283–292. doi: 10.1002/cpt.2453. Epub 2021 Nov 11. PMID: 34664259; PMCID: PMC9298732.

3. Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015 Dec 23;1(6):417–425. doi: 10.1016/j.cels.2015.12.004. PMID: 26771021; PMCID: PMC4707969.

4. Jiménez-Sánchez A, Cast O, Miller ML. Comprehensive benchmarking and integration of tumor microenvironment cell estimation methods. Cancer Res. 2019 Dec 15;79(24):6238–6246. doi: 10.1158/0008–5472.CAN-18–3560. Epub 2019 Oct 22. PMID: 31641033.

5. Martincorena I, Raine KM, Gerstung M, Dawson KJ, Haase K, Van Loo P, Davies H, Stratton MR, Campbell PJ. Universal patterns of selection in cancer and somatic tissues. Cell. 2017 Nov 16;171(5):1029–1041.e21. doi: 10.1016/j.cell.2017.09.042. Epub 2017 Oct 19. Erratum in: Cell. 2018 Jun 14;173(7):1823. PMID: 29056346; PMCID: PMC5720395.

Ethics Approval All ethics and consent have been obtained in accordance with Tempus Labs IRB approval supporting the use of de-identified data.

Consent All ethics and consent have been obtained in accordance with Tempus Labs IRB approval supporting the use of de-identified data.

Abstract 620 Figure 1

Clinical and immunogenomic features of acquired and primary resistance to ICB

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.